Journal of Cancer Research and Therapeutic Oncology最新文献

{"title":"A Pediatric Nasal Esthesioneuroblastoma Treated by Helical Tomotherapy","authors":"M. F. Çetindağ, Y. Cihan, F. Altıntaş","doi":"10.13189/COR.2014.020501","DOIUrl":"https://doi.org/10.13189/COR.2014.020501","url":null,"abstract":"Purpose: To compare 3-dimensional conformal radiotherapy (3DCRT) with intensity modulated radiotherapy (IMRT) in the irradiation of pediatric head and neck tumor. Case report: A 13-year old boy with the diagnosis of olfactory neuroblastoma (stage Kadish B), who had postoperative residual disease referred to our clinic for adjuvant radiotherapy (RT). A total of 60 Gy image guided (IG)-IMRT were applied in two phases (50Gy/30 fractions and 10 Gy/5 fractions). Before irradiation, RT planning was performed by in two different therapy techniques, namely 3DCRT and IMRT, and these techniques were compared regarding conformation number (CN) and homogeneity index (HI) for planning target volume (PTV), as well as maximum, minimum and mean doses for selected critical organs and PTV. Results: IMRT planning with helical tomotherapy had an apparent superiority compared to 3DCRT planning, as expected. The patient was maintaining remission after 26 months from RT and no side effect related to RT were detected. Conclusions: Today, irradiation of pediatric tumors with 3DCRT is the standard practice. However, IMRT may be required in case of tumors at close proximity to the critical organs in which high dose of irradiation is indicated.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90404303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of Breast Cancer Subtypes Based on ER, PR and HER2 Expression with Axillary Lymph Node Status","authors":"Elsayed M Ali, Ahmed R. H. Ahmed, Ayman M. A. Ali","doi":"10.13189/cor.2014.020402","DOIUrl":"https://doi.org/10.13189/cor.2014.020402","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86316736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Melanin-Targeted Radiotherapy in Combination with Radiosensitizing Drugs for the Treatment of Melanoma","authors":"S. Hutchison, C. Rae, M. Tesson, J. Babich, M. Boyd, R. Mairs","doi":"10.13189/COR.2014.020403)","DOIUrl":"https://doi.org/10.13189/COR.2014.020403)","url":null,"abstract":"The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical models. Our purpose was to determine the potential of radiosensitizers to enhance the anti-tumor efficacy of [131I]MIP-1145. Melanotic (A2058) and amelanotic (A375 and SK-N-BE(2c)) cells were treated with [131I]MIP-1145 as a single agent or in combination with drugs with radiosenitizing potential. Cellular uptake of [131I]MIP-1145 and toxicity were assessed in monolayer culture. The interaction between radiosensitizers and [131I]MIP-1145 was evaluated by combination index analysis in monolayer cultures and by delayed growth of multicellular tumor spheroids. [131I]MIP-1145 was taken up by and was toxic to melanotic cells but not amelanotic cells. Combination treatments comprising [131I]MIP-1145 with the topoisomerase inhibitor topotecan or the PARP-1 inhibitor AG014699 resulted in synergistic clonogenic cell kill and enhanced delay of the growth of spheroids derived from melanotic melanoma cells. The proteasome inhibitor bortezomib had no synergistic cytotoxic effect with [131I]MIP-1145 and failed to enhance the delay of spheroid growth. Following combination treatment of amelanotic cells, neither synergistic clonogenic cell kill nor enhanced growth delay of spheroids was observed.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87354928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Health Belief Model in Motivating for Tobacco Cessation and to Improving Knowledge, Attitude and Behavior of Tobacco Users","authors":"P. Renuka, K. Pushpanjali, Ramaiah Dental","doi":"10.13189/COR.2014.020401","DOIUrl":"https://doi.org/10.13189/COR.2014.020401","url":null,"abstract":"There is an alarming increase in tobacco use in younger generation & it is responsible for 90% of oral cancers. A quasi-experimental study was conducted in dental health care settings to assess the effectiveness of health education in improving knowledge, attitude and behaviors of current tobacco users, towards tobacco use, among the patients visiting dental health settings. Study comprised of 20-35 years 88 current tobacco users. Health education was based on the Health Belief Model (HBM). Questionnaire was used to assess knowledge, attitude, and behavior of subjects. Leaflet and video were prepared for aid in health education Descriptive analysis, Paired t-test, Stratified analysis, Pearson Correlation analysis were employed. Improvement in decision to enl in to the tobacco cessation program was 33.7%. There was a statistical significant improvement in knowledge and attitude, of all subjects, in behavior domain significant improvement seen in subjects aged between 20-25 years, literate, smokers, and those utilizing dental health care services more than once in a year. Results of this study concluded that health education based on HBM was effective in motivating to enroll in to tobacco cessation program and improving knowledge and attitude of the tobacco users towards tobacco use and in improving behaviors of younger subjects, literates, smokers and subjects utilizing the dental health services more than once in year.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89141173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Neoplastic Cytotoxicity of Gemcitabine-(C₄-<i>amide</i>)-[anti-EGFR] in Dual-combination with Epirubicin-(C₃-<i>amide</i>)-[anti-HER2/<i>neu</i>] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.","authors":"C P Coyne, Toni Jones, Ryan Bear","doi":"10.17303/jcrto.2014.203","DOIUrl":"10.17303/jcrto.2014.203","url":null,"abstract":"<p><strong>Aims: </strong>Delineate the feasibility of simultaneous, dual selective \"targeted\" chemotherapeutic delivery and determine if this molecular strategy can promote higher levels anti-neoplastic cytotoxicity than if only one covalent immunochemotherapeutic is selectively \"targeted\" for delivery at a single membrane associated receptor over-expressed by chemotherapeutic-resistant mammary adenocarcinoma.</p><p><strong>Methodology: </strong>Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/<i>neu</i> utilizing a rapid multi-phase synthetic organic chemistry reaction scheme. Determination that 96% or greater gemcitabine or epirubicin content was covalently bond to immunoglobulin fractions following size separation by micro-scale column chromatography was established by methanol precipitation analysis. Residual binding-avidity of gemcitabine-(C₄-<i>amide</i>)-[anti-EG-FR] applied in dual-combination with epirubicin-(C₃-<i>amide</i>)-[anti-HER2/<i>neu</i>] was determined by cell-ELIZA utilizing chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations. Lack of fragmentation or polymerization was validated by SDS-PAGE/immunodetection/chemiluminescent autoradiography. Anti-neoplastic cytotoxic potency was determined by vitality stain analysis of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayers known to uniquely over-express EGFR (2 × 10⁵/cell) and HER2/<i>neu</i> (1 × 10⁶/cell) receptor complexes. The covalent immunochemotherapeutics gemcitabine-(C₄-<i>amide</i>)-[anti-EGFR] and epirubicin-(C₃-<i>amide</i>)-[anti-HER2/<i>neu</i>] were applied simultaneously in dual-combination to determine their capacity to collectively evoke elevated levels of anti-neoplastic cytotoxicity. Lastly, the tubulin/microtubule inhibitor mebendazole evaluated to determine if it's potential to complemented the anti-neoplastic cytotoxic properties of gemcitabine-(C4-<i>amide</i>)-[anti-EGFR] in dual-combination with epirubicin-(C₃-<i>amide</i>)-[<i>anti-HER2/neu</i>].</p><p><strong>Results: </strong>Dual-combination of gemcitabine-(C₄-<i>amide</i>)-[anti-EGFR] with epirubicin-(C₃-<i>amide</i>)-[anti-HER2/<i>neu</i>] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone. The benzimidazole microtubule/tubulin inhibitor, mebendazole complemented the anti-neoplastic cytotoxicity of gemcitabine-(C₄-<i>amide</i>)-[anti-EGFR] in dual-combination with epirubicin-(C₃-<i>amide</i>)-[<i>anti-HER2/neu</i>].</p><p><strong>Conclusions: </strong>The dual-combination of gemcitabine-(C₄-<i>amide</i>)-[anti-EGFR] with epirubicin-(C₃-<i>amide</i>)-[anti-HER2/<i>neu</i>] produced higher levels of selectively \"targeted\" anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) than either covalen","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33191010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOLFIRINOX in Advanced Pancreatic Cancer, NEMROCK Experience","authors":"Elghonemy E., Selim H., S. A, Shukur H.","doi":"10.13189/cor.2014.020302","DOIUrl":"https://doi.org/10.13189/cor.2014.020302","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81809192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcome of Rhabdomyosarcoma (RMS) in Egyptian Children: Experience of the National Cancer Institute-Egypt","authors":"M. Fawzy, M. Sedki, Hosam El Zomor, Hanaa M. Rashad, A. Mohamed, A. Nasr","doi":"10.13189/COR.2014.020202","DOIUrl":"https://doi.org/10.13189/COR.2014.020202","url":null,"abstract":"Background. Survival rates of pediatric Rhabdomyosarcoma (RMS) have been tremendously improved during the last decade by the development of risk stratification. This has favored tailoring treatment using multi-therapeutic modalities. Methods. Upfront surgical resection was followed by systemic chemotherapy using Vincristine/Actinomycine-D/Cyclophosphamide (VAC) regimen with subsequent further local control by surgery and or radiotherapy according to risk stratification status. Results. Study included 40 patients; their median age was 3.5 years (range: 8 m to 17 yrs) with M/F: 28/12. The 2 years Overall Survival (OS) and Event Free Survival (EFS) for all study patients was 87% and 45% respectively. By univariate analysis, OS was 100% if CR (complete response) versus 92% if PR (partial response) (p=0.03), and was 94% if no distant metastasis versus 66% if present (p=0.024). On the other hand, EFS was 88% with CR versus 46% in PR patients (p <0.001), and was 80% if upfront surgery was done versus 33% if only simple biopsy taken (p=0.03). Local radiotherapy versus no radiotherapy was highly associated with EFS difference as well (75% versus 0%, respectively; p<0.001). In multivariate analysis, local radiotherapy found to be an independent prognostic factor of EFS (95% CI: 2.5-31). Conclusion. Disease extent as well as treatment response are two important factors influenced survival in our RMS patients. Local control measures including surgical resection as well as radiotherapy are crucial variables that predicted EFS. The poor outcome of patients with metastatic disease necessitates further therapeutic approaches.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80353555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Risk Factors Related to Head and Neck Squamous Cell Carcinoma (HNSCC) Among College Students","authors":"Sloane C. Burke, Karen Smith, S. Sharmin, Cr Winkelman","doi":"10.13189/COR.2014.020102","DOIUrl":"https://doi.org/10.13189/COR.2014.020102","url":null,"abstract":"The incidence of head and neck cancers among young individuals is increasing in the United States. Various sexual behaviors, heavy tobacco and alcohol use, HPV infection, and lack of HPV vaccination may increase the risk of head and neck cancer in the younger male population. The study was conducted to identify the risk factors for head and neck squamous cell cancers (HNSCC) among college students. A convenience sample of 1,685 students from an undergraduate health course was selected for the study. The self-reported, anonymous electronic questionnaire included items on the following risk factors: tobacco and alcohol use, HPV infection and/or presence of genital warts, oral hygiene, open-mouth kissing, and practice of various sexual behaviors. Statistical results showed that among college-aged males, the use of tobacco products and alcohol is much higher than females (P=0.000). Significance was also found between gender and sexual behaviors in one's lifetime and within the past 12 months (P=0.000). On average, males have higher numbers of vaginal and oral sex partners than females. In addition, males reported having twice the number of open-mouth kissing partners compared to their female counterparts (6 as opposed to 3). Importantly, the percentage of males who completed all three HPV vaccinations in the series is much lower (10.1%) than females (89.9%) which make them more vulnerable to HPV transmission, thus increasing the risk of HNSCC. College-aged males seem to be engaged in more high-risk activities related to HNSCC compared to their female counterparts. Integration of preventive public health strategies should be considered.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74812434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant","authors":"D. Riese, Richard M. Gallo, Ianthe N. Bryant, Christopher P. Mill, Steven Kaverman","doi":"10.17303/JCRTO.2013.1.104","DOIUrl":"https://doi.org/10.17303/JCRTO.2013.1.104","url":null,"abstract":"ErbB4 (HER4) is a member of the ErbB family of receptor tyrosine kinases, which includes the Epidermal Growth Factor Receptor (EGFR/ErbB1), ErbB2 (HER2/Neu), and ErbB3 (HER3). Mounting evidence indicates that ErbB4, unlike EGFR or ErbB2, functions as a tumor suppressor in many human malignancies. Previous analyses of the constitutively-dimerized and –active ErbB4 Q646C mutant indicate that ErbB4 kinase activity and phosphorylation of ErbB4 Tyr1056 are both required for the tumor suppressor activity of this mutant in human breast, prostate, and pancreatic cancer cell lines. However, the cytoplasmic region of ErbB4 possesses additional putative functional motifs, and the contributions of these functional motifs to ErbB4 tumor suppressor activity have been largely underexplored. Here we demonstrate that ErbB4 BH3 and LXXLL motifs, which are thought to mediate interactions with Bcl family proteins and steroid hormone receptors, respectively, are required for the tumor suppressor activity of the ErbB4 Q646C mutant. Furthermore, abrogation of the site of ErbB4 cleavage by gamma-secretase also disrupts the tumor suppressor activity of the ErbB4 Q646C mutant. This last result suggests that ErbB4 cleavage and subcellular trafficking of the ErbB4 cytoplasmic domain may be required for the tumor suppressor activity of the ErbB4 Q646C mutant. Indeed, here we demonstrate that mutants that disrupt ErbB4 kinase activity, ErbB4 phosphorylation at Tyr1056, or ErbB4 cleavage by gamma-secretase also disrupt ErbB4 trafficking away from the plasma membrane and to the cytoplasm. This supports a model for ErbB4 function in which ErbB4 tumor suppressor activity is dependent on ErbB4 trafficking away from the plasma membrane and to the cytoplasm, mitochondria, and/or the nucleus.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82299885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.","authors":"Richard M Gallo,&nbsp;Ianthe N Bryant,&nbsp;Christopher P Mill,&nbsp;Steven Kaverman,&nbsp;David J Riese","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>ErbB4 (HER4) is a member of the ErbB family of receptor tyrosine kinases, which includes the Epidermal Growth Factor Receptor (EGFR/ErbB1), ErbB2 (HER2/Neu), and ErbB3 (HER3). Mounting evidence indicates that ErbB4, unlike EGFR or ErbB2, functions as a tumor suppressor in many human malignancies. Previous analyses of the constitutively-dimerized and -active ErbB4 Q646C mutant indicate that ErbB4 kinase activity and phosphorylation of ErbB4 Tyr1056 are both required for the tumor suppressor activity of this mutant in human breast, prostate, and pancreatic cancer cell lines. However, the cytoplasmic region of ErbB4 possesses additional putative functional motifs, and the contributions of these functional motifs to ErbB4 tumor suppressor activity have been largely underexplored. Here we demonstrate that ErbB4 BH3 and LXXLL motifs, which are thought to mediate interactions with Bcl family proteins and steroid hormone receptors, respectively, are required for the tumor suppressor activity of the ErbB4 Q646C mutant. Furthermore, abrogation of the site of ErbB4 cleavage by gamma-secretase also disrupts the tumor suppressor activity of the ErbB4 Q646C mutant. This last result suggests that ErbB4 cleavage and subcellular trafficking of the ErbB4 cytoplasmic domain may be required for the tumor suppressor activity of the ErbB4 Q646C mutant. Indeed, here we demonstrate that mutants that disrupt ErbB4 kinase activity, ErbB4 phosphorylation at Tyr1056, or ErbB4 cleavage by gamma-secretase also disrupt ErbB4 trafficking away from the plasma membrane and to the cytoplasm. This supports a model for ErbB4 function in which ErbB4 tumor suppressor activity is dependent on ErbB4 trafficking away from the plasma membrane and to the cytoplasm, mitochondria, and/or the nucleus.</p>","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"1 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2013-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32310331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}